Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahesh K B Parmar

Showing results (1-10 of 150) with videos related to

Pageof 15
Sort By:
BMC Medical Research Methodology|February 13, 2016
Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipatedPatrick Royston, Mahesh K B Parmar
BMC Medical Research Methodology|December 10, 2013
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcomePatrick Royston, Mahesh K B Parmar
Trials|August 8, 2014
An approach to trial design and analysis in the era of non-proportional hazards of the treatment effectPatrick Royston, Mahesh K B Parmar
Statistics in Medicine|September 5, 2002
Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effectsPatrick Royston, Mahesh K B Parmar
Statistics in Medicine|May 26, 2011
The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubtPatrick Royston, Mahesh K B Parmar
Trials|April 8, 2020
A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcomePatrick Royston, Mahesh K B Parmar
Journal of Clinical Epidemiology|January 30, 2008
Interim monitoring of efficacy data is important and appropriateMatthew R Sydes, Mahesh K B Parmar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Observations on the interpretation of clinical trials in early ovarian cancerAnn Marie C Swart, Mahesh K B Parmar
Statistics in Medicine|July 11, 2003
Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancerPatrick Royston, Mahesh K B Parmar, Wendi Qian
Statistics in Medicine|March 18, 2004
Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancerPatrick Royston, Mahesh K B Parmar, Richard Sylvester
Pageof 15

Showing results (1-10 of 150) with videos related to

Sort By:
Pageof 15
BMC Medical Research Methodology|February 13, 2016
Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipatedPatrick Royston, Mahesh K B Parmar
BMC Medical Research Methodology|December 10, 2013
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcomePatrick Royston, Mahesh K B Parmar
Trials|August 8, 2014
An approach to trial design and analysis in the era of non-proportional hazards of the treatment effectPatrick Royston, Mahesh K B Parmar
Statistics in Medicine|September 5, 2002
Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effectsPatrick Royston, Mahesh K B Parmar
Statistics in Medicine|May 26, 2011
The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubtPatrick Royston, Mahesh K B Parmar
Trials|April 8, 2020
A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcomePatrick Royston, Mahesh K B Parmar
Journal of Clinical Epidemiology|January 30, 2008
Interim monitoring of efficacy data is important and appropriateMatthew R Sydes, Mahesh K B Parmar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Observations on the interpretation of clinical trials in early ovarian cancerAnn Marie C Swart, Mahesh K B Parmar
Statistics in Medicine|July 11, 2003
Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancerPatrick Royston, Mahesh K B Parmar, Wendi Qian
Statistics in Medicine|March 18, 2004
Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancerPatrick Royston, Mahesh K B Parmar, Richard Sylvester
Pageof 15